


Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 016915-0252		SERIAL NO. Unassigned		
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)				APPLICANT Gerd GEISSLINGER et al.				
				FILING DATE December 7, 2001		GROUP ART UNIT Unassigned		
<b>U.S. PATENT DOCUMENTS</b>								
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
6	A1	4,788,219	Nov. 29, 1988	Sakurai et al.				
6	A2	5,057,304	Oct. 15, 1991	Eichelbaum et al.				
6	A3	5,817,800	Oct. 6, 1998	Hoos et al.				
<b>FOREIGN PATENT DOCUMENTS</b>								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
6	A4	0 595 133	May 4, 1994	EPO				
6	A5	0 647 450	April 12, 1995	EPO				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
6	A6	Desbene et al., "Application of the ADEPT Strategy to the MDR Resistance in Cancer Chemotherapy," Anti-Cancer Drug Design, Vol. 14, No. 2 (April 1999), pp. 93-106.						
6	A7	Sperker et al., "Drug Targeting by Glucuronide Prodrugs: Regulation of the Bioactivating Enzyme Beta-Glucuronidase in the Hepatoma Cell Line HEPG2," Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 357, No. 4, Suppl., PP. R19, Meeting Info.: 39 <sup>th</sup> Spring Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology, Mainz, Germany, March 17-19, 1998; German Society.						
6	A8	Sperker et al., "The Role of Beta-Glucuronidase in Drug Disposition and Drug Targeting in Humans," Clinical Pharmacokinetics, Vol. 33, No. 1 (1997), pp. 18-31. <i>Duplicate</i>						
6	A9	Bosslet et al., "Elucidation of the Mechanism Enabling Tumor Selective Prodrug-Monotherapy," Cancer Research, Vol. 58, No. 6 (March 15, 1998), pp. 1195-1201. <i>Duplicate</i>						
EXAMINER <i>BL</i>				DATE CONSIDERED <i>6-3-03</i>				
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.								

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 016915-0252	SERIAL NO. 09/980,824
<b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Gerd GEISSLINGER et al.	
		FILING DATE 12/07/2001	GROUP ART UNIT Unassigned
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
5	A13	Sperker et al., "Inhibition of Escherichia Coli $\beta$ -Glucuronidase by Verapamil: Effect on Enterohepatic Cycling of Morphine/Morphine-6-Glucuronide in Rats," European Journal of Clinical Pharmacology, p. 55 (1999).	
6	A14	Mickisch et al., "Dexverapamil to Modulate Vinblastine Resistance in Metastatic Renal Cell Carcinoma," Cancer Research Clinic of Oncology, Vol. 121, pp. R11-R16 (1995).	
6	A15	Volm, "Multidrug Resistance and its Reversal," Anticancer Research, Vol. 18, pp. 2905-2918 (1998).	
6	A16	Wainer, "Stereoisomers in Clinical Oncology: Why it is Important to Know What the Right and Left Hands are Doing," Annals of Oncology, Vol. 4, pp. S7-S13 (1993).	
6	A17	Simpson, "The Calcium Channel Blocker Verapamil and Cancer Chemotherapy," Cell Calcium, Vol. 6, pp. 449-467 (1985).	
6	A18	Ling, "Multidrug Resistance: Molecular Mechanisms and Clinical Relevance," Cancer Chemotherapy Pharmacology, Vol. 40, pp. S3-S8 (1997).	
6	A19	Aasmundstad et al., "Different Biotransformation of Morphine in Isolated Liver Cells from Guinea Pig and Rat," Biochemical Pharmacology, Vol. 46, No. 6, pp. 961-968 (1993).	
6	A20	Shah et al., "The Calcium Channel Antagonist, Verapamil, Potentiates the Inhibitory Action of Morphine on Intestinal and Biliary Motility," Journal of Pharmaceutical Pharmacology, Vol. 39, pp. 1037-1038 (pp. 1987).	
6	A21	Krevsky et al., "Effect of Verapamil on Human Intestinal Transit," Digestive Diseases and Sciences, Vol. 37, No. 6, pp. 919-924 (1992).	
6	A22	Schmidt et al., "Opioid Receptor Agonist Potencies of Morphine and Morphine-6-Glucuronide in the Guinea-Pig Ileum," European Journal of Pharmacology, Vol. 255, pp. 245-247 (1994).	
6	A23	Hartley et al., "Analysis of Morphine and its 3- and 6-Glucuronides by High Performance Liquid Chromatography with Fluorimetric Detection Following Solid Phase Extraction from Neonatal Plasma," Biomedical Chromatography, Vol. 7, pp. 34-37 (1993).	
6	A24	Lowry et al., "Protein Measurement with the Folin Phenol Reagent," Journal of Biological Chemistry, Vol. 193, pp. 265-275 (1951).	
6	A25	Sperker et al., "Interindividual Variability in Expression and Activity of Human $\beta$ -Glucuronidase in Liver and Kidney: Consequences for Drug Metabolism," The Journal of Pharmacology and Experimental Therapeutics, Vol. 281, No. 2, pp. 914-920 (1997).	



6-2-03

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 016915-0252		SERIAL NO. 09/980,824		
<b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>				APPLICANT Gerd GEISSLINGER et al.				
				FILING DATE 12/07/2001		GROUP ART UNIT Unassigned		
<b>U.S. PATENT DOCUMENTS</b>								
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
G	A1	5,447,719	Sept. 5, 1995	Kamataki	424	195.1		
G	A2	5,817,800	Oct. 6, 1998	Bosslet et al.	536	53		
<b>FOREIGN PATENT DOCUMENTS</b>								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
G	A3	0 822 192	Feb. 4, 1998	EPO	1	1		Abstract
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
G	A4	Bernacki et al., "Glycosidases in Cancer and Invasion," Cancer and Metastasis Reviews, Vol. 4, pp. 81-101 (1985).						
G	A5	Nakajima et al., "Heparanases and Tumor Metastasis," Journal of Cellular Biochemistry, Vol. 36, pp. 157-167 (1988).						
G	A6	Niwa et al., "A New Potent $\beta$ -Glucuronidase Inhibitor, D-Glucaro- $\delta$ -lactam Derived from Nojirimycin," Journal of Biochemistry, Vol. 72, pp. 207-211 (1972).						
G	A7	Takasuna et al., "Protective Effects of <i>Kampo</i> Medicines and Baicalin against Intestinal Toxicity of a New Anticancer Camptothecin Derivative, Irinotecan Hydrochloride (CPT-11), in Rats," Japanese Journal of Cancer Research, Vol. 86, pp. 978-984 (1995).						
G	A8	Sperker et al., "The Role of $\beta$ -Glucuronidase in Drug Disposition and Drug Targeting in Humans," Clinical Pharmacokinetics, Vol. 33, No. 1, pp. 18-31 (1997).						
G	A9	Bosslet et al., "Fusion Protein Mediated Prodrug Activation (FMPA) In Vivo," Cell Biophysics, Vols. 24-25 (1994).						
G	A10	Bosslet et al., "Tumor-selective Prodrug Activation by Fusion Protein-mediated Catalysis," Cancer Research, Vol. 54, pp. 2151-2159 (1994).						
G	A11	Bosslet et al., "Elucidation of the Mechanism Enabling Tumor Selective Prodrug Monotherapy," Cancer Research, Vol. 58, pp. 1195-1201 (1998).						
G	A12	Mürdter et al., "Enhanced Uptake of Doxorubicin into Bronchial Carcinoma: $\beta$ -Glucuronidase Mediates Release of Doxorubicin from a Glucuronide Prodrug (HMR 1826) at the Tumor Site," Cancer Research, Vol. 57, pp. 2440-2445 (1997).						
EXAMINER 				DATE CONSIDERED 6-2-03				
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.								